CN106749535A - 云南臭蛙降血糖肽及制备方法及其应用 - Google Patents
云南臭蛙降血糖肽及制备方法及其应用 Download PDFInfo
- Publication number
- CN106749535A CN106749535A CN201611189143.7A CN201611189143A CN106749535A CN 106749535 A CN106749535 A CN 106749535A CN 201611189143 A CN201611189143 A CN 201611189143A CN 106749535 A CN106749535 A CN 106749535A
- Authority
- CN
- China
- Prior art keywords
- yunnan
- blood sugar
- sugar reducing
- reducing peptide
- smelly frog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 117
- 239000008280 blood Substances 0.000 title claims abstract description 117
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 109
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 19
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 230000001737 promoting effect Effects 0.000 claims abstract description 4
- 210000000416 exudates and transudate Anatomy 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 28
- 102000004877 Insulin Human genes 0.000 abstract description 15
- 108090001061 Insulin Proteins 0.000 abstract description 15
- 229940125396 insulin Drugs 0.000 abstract description 14
- 241001465754 Metazoa Species 0.000 abstract description 11
- 230000003578 releasing effect Effects 0.000 abstract description 7
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- 210000000496 pancreas Anatomy 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 210000004153 islets of langerhan Anatomy 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 108010011459 Exenatide Proteins 0.000 description 9
- 108700026244 Open Reading Frames Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 229960001519 exenatide Drugs 0.000 description 7
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 5
- 241001510218 Odorrana andersonii Species 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 101800001442 Peptide pr Proteins 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 239000002808 molecular sieve Substances 0.000 description 4
- 238000007410 oral glucose tolerance test Methods 0.000 description 4
- 238000000734 protein sequencing Methods 0.000 description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 3
- AAKRWBIIGKPOKQ-ONGXEEELSA-N Leu-Val-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AAKRWBIIGKPOKQ-ONGXEEELSA-N 0.000 description 3
- ITWQLSZTLBKWJM-YUMQZZPRSA-N Lys-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCCCN ITWQLSZTLBKWJM-YUMQZZPRSA-N 0.000 description 3
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 3
- DJEVQCWNMQOABE-RCOVLWMOSA-N Val-Gly-Asp Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)O)N DJEVQCWNMQOABE-RCOVLWMOSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 108010015792 glycyllysine Proteins 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 108010034529 leucyl-lysine Proteins 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- XVZCXCTYGHPNEM-IHRRRGAJSA-N (2s)-1-[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O XVZCXCTYGHPNEM-IHRRRGAJSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000269350 Anura Species 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- 241000132931 Batrachia Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000269436 Ranidae Species 0.000 description 2
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 2
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- FPCIBLUVDNXPJO-XPUUQOCRSA-N Val-Cys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O FPCIBLUVDNXPJO-XPUUQOCRSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 108010027668 glycyl-alanyl-valine Proteins 0.000 description 2
- 239000000864 hyperglycemic agent Substances 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 108010027338 isoleucylcysteine Proteins 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000002708 spider venom Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- CWNPOQFCIIFQDM-UHFFFAOYSA-N 3-nitrobenzyl alcohol Chemical compound OCC1=CC=CC([N+]([O-])=O)=C1 CWNPOQFCIIFQDM-UHFFFAOYSA-N 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- WKOBSJOZRJJVRZ-FXQIFTODSA-N Ala-Glu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WKOBSJOZRJJVRZ-FXQIFTODSA-N 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- RVDVDRUZWZIBJQ-CIUDSAMLSA-N Arg-Asn-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O RVDVDRUZWZIBJQ-CIUDSAMLSA-N 0.000 description 1
- RVMXMLSYBTXCAV-VEVYYDQMSA-N Asp-Pro-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMXMLSYBTXCAV-VEVYYDQMSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- VOBMMKMWSIVIOA-SRVKXCTJSA-N Cys-Lys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N VOBMMKMWSIVIOA-SRVKXCTJSA-N 0.000 description 1
- 210000002334 D-cell of pancreatic islet Anatomy 0.000 description 1
- PBEQPAZRHDVJQI-SRVKXCTJSA-N Glu-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)N PBEQPAZRHDVJQI-SRVKXCTJSA-N 0.000 description 1
- PCBBLFVHTYNQGG-LAEOZQHASA-N Glu-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N PCBBLFVHTYNQGG-LAEOZQHASA-N 0.000 description 1
- BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 1
- SJJHXJDSNQJMMW-SRVKXCTJSA-N Glu-Lys-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O SJJHXJDSNQJMMW-SRVKXCTJSA-N 0.000 description 1
- UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 241000270431 Heloderma suspectum Species 0.000 description 1
- CNMOKANDJMLAIF-CIQUZCHMSA-N Ile-Thr-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O CNMOKANDJMLAIF-CIQUZCHMSA-N 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- KPYAOIVPJKPIOU-KKUMJFAQSA-N Leu-Lys-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O KPYAOIVPJKPIOU-KKUMJFAQSA-N 0.000 description 1
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 1
- XOEDPXDZJHBQIX-ULQDDVLXSA-N Leu-Val-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XOEDPXDZJHBQIX-ULQDDVLXSA-N 0.000 description 1
- LQTGGXSOMDSWTQ-UNQGMJICSA-N Met-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCSC)N)O LQTGGXSOMDSWTQ-UNQGMJICSA-N 0.000 description 1
- LBSWWNKMVPAXOI-GUBZILKMSA-N Met-Val-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O LBSWWNKMVPAXOI-GUBZILKMSA-N 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- SMFGCTXUBWEPKM-KBPBESRZSA-N Phe-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 SMFGCTXUBWEPKM-KBPBESRZSA-N 0.000 description 1
- TYMBHHITTMGGPI-NAKRPEOUSA-N Pro-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H]1CCCN1 TYMBHHITTMGGPI-NAKRPEOUSA-N 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 241000269435 Rana <genus> Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- VZQRNAYURWAEFE-KKUMJFAQSA-N Ser-Leu-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 VZQRNAYURWAEFE-KKUMJFAQSA-N 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- GLQFKOVWXPPFTP-VEVYYDQMSA-N Thr-Arg-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O GLQFKOVWXPPFTP-VEVYYDQMSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- -1 amino acid Glucagon-like peptide -1) analog Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940084891 byetta Drugs 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000010429 evolutionary process Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010040030 histidinoalanine Proteins 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000002795 scorpion venom Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000000917 skin toxin Substances 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明涉及一种云南臭蛙降血糖肽及制备方法及其在促进胰岛β细胞增殖药物和糖尿病治疗中的应用。云南臭蛙降血糖肽具有序列表SEQ ID NO:1所示的氨基酸序列,可从云南臭蛙皮肤分泌液中分离得到。云南臭蛙降血糖肽具有促进胰岛β细胞增殖及胰岛素释放的显著特点,可明显降低2型糖尿病模型动物的血糖,具有结构简单、人工合成方便的有益特点。可应用于促进胰岛β细胞增殖药物和糖尿病治疗药物的制备。
Description
技术领域
本发明提供了一种来源于两栖动物云南臭蛙降血糖肽及制备方法及其应用,属生物医学领域。
背景技术
在自然界漫长的进化过程中,很多动物都产生了具有特定生物学活性的肽类分子,作为高效能的防御和捕食的分子武器,如蛇毒、蝎毒、蜘蛛毒素、蛙皮毒素等。自然界亿万年的“加速进化选择”赋予动物多肽类活性分子具有高活力(较其它类型化合物活性高103-106倍)和高选择性的特征(可有效区分膜离子通道亚型);另一方面,在协同进化驱使下,动物多肽类活性分子广泛存在多拷贝基因家族和高进化速率,从而呈现惊人的分子水平生物多样性,如每种蜘蛛毒素至少有300种活性多肽、每种蝎子至少有100种以上的活性多肽,估计自然界中的有毒动物含有3000万种以上的活性多肽。天然活性多肽已成为新药作用靶点发现与确认的有力工具以及新药创制先导化合物的重要来源,在基础科学研究、新兴生物产业、创新药物研发中具有独特和不可替代的作用。
艾塞那肽Exenatide(商品名Byetta)是由Amylin Pharmaceuticals与礼来(EliLilly)公司共同开发的新型2型糖尿病治疗药物。Exendin-4最初是由被称为“希拉巨蜥”的美国大毒蜥(Heloderma suspectum)分离纯化得到的,是一种含有39个氨基酸的GLP-1(胰高血糖素样肽-1)类似物,其一级结构与人GLP-1有53%的同源性,但显示出更强的稳定性和更长效的作用。艾塞那肽最终被礼来公司开发成化学合成药物,其氨基酸序列与天然纯化的Exendin-4完全相同,化学合成的Exendin-4被称为Exenatide。2009年8月艾塞那肽在我国上市,国内商品名为“百泌达”。百泌达具有全新的降糖机制,用于二甲双胍、磺酰脲类或二甲双胍与磺酰脲类联合应用不能充分控制血糖的2型糖尿病患者,已成为生物医药中连续多年销售额超过十亿美元的“重磅炸弹”。艾塞那肽的成功表明了从天然动物肽类活性分子发掘新型2型糖尿病治疗药物的现实可行性。
两栖类动物皮肤分泌物中含有大量未知功能的活性多肽。蛙科臭蛙属在整个两栖类动物的进化中占有重要位置,是蛙科动物从真蛙类向水蛙类进化的重要过渡类群。我们从云南、贵州、四川等地采集到了中国特有的9种臭蛙,通过蛋白质组学和基因组学手段,从这9种臭蛙皮肤里面识别了728条不同的成熟活性肽分子,其中662条为首次报道。这些活性肽被分为97个家族,其中71个家族为首次命名。臭蛙活性肽具有抗菌、抗氧化、免疫调节和促进胰岛素释放等多种生物学活性(Yang X,Lee WH,Zhang Y.Extremely abundantantimicrobial peptides existed in the skins of nine kinds of Chinese odorousfrogs.J Proteome Res.2012,11:306-319.)
发明内容
本发明的目的是提供一种云南臭蛙(Odorrana andersonii)降血糖肽及其制备方法,本发明还提供云南臭蛙降血糖肽在促进胰岛β细胞增殖药物和糖尿病治疗中的应用。云南臭蛙降血糖肽具有促进胰岛β细胞增殖及胰岛素释放的显著特点,可明显降低2型糖尿病模型动物的血糖。云南臭蛙降血糖肽具有结构简单、人工合成方便的有益特点。可应用于促进胰岛β细胞增殖药物和糖尿病治疗药物的制备。
为了实现本发明的目的,本发明提供了如下技术方案:
云南臭蛙Odorrana andersonii降血糖肽OA-A1,所述降血糖肽具有下述序列表SEQ ID NO:1所示的氨基酸序列:Leu Val Gly Lys Leu Leu Lys Gly Ala Val Gly AspVal Cys Gly Leu Leu Pro Ile Cys。
本发明同时提供了云南臭蛙降血糖肽前体及成熟肽的核苷酸序列或其互补序列,所述核苷酸序列编码本发明的云南臭蛙降血糖肽前体及成熟肽。
本发明的云南臭蛙降血糖肽的制备方法,从云南臭蛙皮肤分泌液中分离得到,纯化的云南臭蛙降血糖肽OA-A1具有SEQ ID NO:1所示的氨基酸序列,即从云南臭蛙皮肤分泌物通过生物化学分离手段,通过分子筛、高压液相反相C18柱分离纯化得到。
本发明的云南臭蛙降血糖肽的制备方法,采用固相化学法合成,合成的云南臭蛙降血糖肽OA-A1具有SEQ ID NO:1所示的氨基酸序列。所述的固相化学法合成即根据分离纯化、活性测定、质谱分子量测定、蛋白质序列测定结合编码云南臭蛙降血糖肽OA-A1前体蛋白的完整开放阅读框(ORF)得到天然云南臭蛙降血糖肽的氨基酸序列,用全自动多肽合成仪合成其全序列;通过高压液相HPLC反相C18柱层析脱盐、纯化;然后用HPLC方法鉴定其纯度,分子量测定采用快原子轰击质谱法(Fast atom bombardment mass spectrometry,FAB-MS),用全自动氨基酸测序仪测定氨基酸序列结构。
本发明云南臭蛙降血糖肽也可以使用本领域技术人员熟知的方法,还可以通过遗传工程的方法制备。
云南臭蛙降血糖肽作为制备促进胰岛β细胞增殖及降血糖药物的应用。
将本发明的云南臭蛙降血糖肽氨基酸序列经蛋白质数据库进行搜寻比较,未发现有任何相同的降血糖肽前体及成熟肽序列。
因此,云南臭蛙降血糖肽具有显著的促进胰岛β细胞增殖和胰岛素释放的作用,在2型糖尿病动物模型上能显著降低模型动物的血糖。与其它来源降血糖肽相比,该降血糖肽具有结构简单、人工合成方便、降血糖作用明确的有益特点。
附图说明
图1为本发明的云南臭蛙降血糖肽开放阅读框核酸序列及其编码的蛋白质序列,其中斜体加框序列为本发云南臭蛙降血糖肽的成熟序列。
图2为本发明的云南臭蛙降血糖肽分子筛层析图谱,图中横线部分为具有促进胰岛素分泌的活性成分。
图3为本发明的云南臭蛙降血糖肽的HPLC层析图谱,图中箭头标示部分为最终分离纯化得到的云南臭蛙降血糖肽。
图4为纯化得到的云南臭蛙降血糖肽质谱分子量测定图谱。
图5为云南臭蛙降血糖肽对小鼠胰岛β细胞增殖和胰岛素释放的影响。A)对小鼠胰岛β细胞增殖的作用;B)对小鼠胰岛β细胞分泌胰岛素的作用。
图6为云南臭蛙降血糖肽对2型糖尿病小鼠血糖及葡萄糖耐受能力(OGTT)的影响。A)对2型糖尿病小鼠血糖的影响;B)对2型糖尿病小鼠葡萄糖耐受能力(OGTT)的影响。
图7为云南臭蛙降血糖肽对小鼠胰岛细胞的影响。A)正常小鼠对照;B)糖尿病小鼠生理盐水对照;C)糖尿病小鼠云南臭蛙降血糖肽1nmol/kg;D)糖尿病小鼠云南臭蛙降血糖肽10nmol/kg。I代表胰岛细胞。
具体实施方式
实施例1云南臭蛙降血糖肽的分离纯化、活性测定及质谱和蛋白质序列测定。
1)云南臭蛙皮肤分泌物的制备:用电理疗仪刺激蛙皮肤,蛙产生大量皮肤分泌物,然后用0.1M pH7.4PBS缓冲液(称取13.97g K2HPO4和2.69g KH2PO4溶于蒸馏水中,定容到1000ml)冲洗皮肤,并收集冲洗液,合并冲洗液经Christ冻干机(型号Alpha 1-4)冰冻干燥得到云南臭蛙皮肤分泌物。
2)云南臭蛙降血糖肽的分离纯化:
2.1分子筛柱层析:将冻干的皮肤分泌物1g用2ml蒸馏水溶解,然后将溶解的分泌物12000转/分离心10分钟,去除沉淀后上清液通过Sephedex-G 75分子筛柱(2.6×100cm)进行分离。缓冲液为:25mM Tris-HCl,pH 7.8,含0.1M的NaCl。流速为3ml/10min,每10min收集1管,并使用分光光度计检测280nm处的吸光值,分子筛柱层析图谱见图2。图2横线部分标示的组分具有促进胰岛素释放活性。
2.2高压液相HPLC柱层析:合并图2具有促进胰岛素释放活性的组分并冻干后,冻干粉用蒸馏水溶解后利用HPLC C18柱(250×4.6mm,kromasil 100-5c18)进行分离纯化。A液为水(含0.1%三氟乙酸),B液为乙腈(含0.1%三氟乙酸),分离图谱见图3,具有促进胰岛素释放活性的组分见图3箭头所示。
3)促胰岛素释放活性检测:小鼠胰腺β细胞株(Beta-Tc-6)培养于含10%胎牛血清(Biological Industries公司)的DMEM高糖培养基(Biological Industries公司)中,将1×105cell/ml密度的细胞按照100μl每孔接种于96孔细胞培养板(Corning公司产品),37℃,5%CO2恒温培养。待细胞贴壁后,弃去含血清的培养基,每孔内加入用无胎牛血清培养基溶解的相应浓度的多肽样品100μl,空白对照加同体积的无胎牛血清培养基。培养24h后收集培养液,于3000转/min离心30min,收集上清,按照RayBiotech公司胰岛素测定试剂盒方法检测上清液中的胰岛素含量,试剂盒为RayBiotech公司小鼠胰岛素测定试剂盒(货号:ELM-Insulin-1)。
4)云南臭蛙降血糖肽质谱和蛋白质序列测定:
4.1云南臭蛙降血糖肽的质谱测定:上述步骤2.2得到的活性成分按仪器操作说明进行处理,利用德国布鲁克公司autoflexTMspeed进行云南臭蛙降血糖肽的MALDI-TOF质谱分子量测定,测定得到的云南臭蛙降血糖肽的[M+H]+分子量为1968.127道尔顿,表示云南臭蛙降血糖肽的实际分子量为1967.127道尔顿,见图4。云南臭蛙降血糖肽分子内形成二硫键的理论分子量为1966.49道尔顿,表明天然纯化的云南臭蛙降血糖肽分子内2个Cys形成了分子内二硫键。
4.2云南臭蛙降血糖肽的N-端蛋白质序列测定:上述步骤2.2得到的活性成分冻干粉按仪器操作说明进行处理,利用SHIMADZU公司PPSQ-31A全自动蛋白质序列仪进行云南臭蛙降血糖肽的N-端蛋白质序列测定,测定得到的云南臭蛙降血糖肽的N-端12个氨基酸残基与序列表SEQ ID NO:2所示的前12个氨基酸序列完全相同,均为:Leu Val Gly Lys LeuLeu Lys Gly Ala Val Gly Asp。
云南臭蛙降血糖肽质谱和蛋白质序列测定结果表明其氨基酸序列与本发明序列表SEQ ID NO:2所示的序列完全相同。
实施例2编码云南臭蛙降血糖肽开放阅读框的核酸序列确定。
1)云南臭蛙皮肤总RNA的提取。剥离云南臭蛙皮肤,立即放入液氮中。4小时后取出液氮中保存的皮肤30mg于液氮中研磨至粉末状。加入10ml总RNA提取缓冲液(Trizol溶液,美国Invitrogen公司产品),于20ml玻璃匀浆器中匀浆30分钟。然后加入等体积的酚/氯仿溶液,剧烈混匀。室温放置10分钟后,4℃,12000rpm离心10分钟,弃沉淀,上清液加入等体积的异丙醇,室温放置10分钟。4℃,12000rpm离心10分钟,沉淀用75%乙醇洗一次,晾干,管底沉淀物即为云南臭蛙皮肤总RNA。
2)云南臭蛙皮肤转录组测定。制备的云南臭蛙皮肤总RNA干冰运输至北京诺禾致源科技股份有限公司,采用Illumina Hiseq平台进行转录本拼接、注释、全方位分析基因表达水平和结构信息,完成云南臭蛙皮肤转录组测定。
云南臭蛙降血糖肽开放阅读框的核酸序列确定。将云南臭蛙降血糖肽N-端12个氨基酸残基序列与云南臭蛙皮肤转录组测定数据进行核酸翻译后蛋白质序列的氨基酸序列比对,得到云南臭蛙降血糖肽编码基因,其开放阅读框(ORF)由216个核苷酸组成,自5’端至3‘端序列为(SEQ ID NO:2):
云南臭蛙降血糖肽开放阅读框(ORF)编码的前体蛋白命名为云南臭蛙降血糖肽前体蛋白OA-A,其氨基酸序列为(SEQ ID NO:3):
云南臭蛙降血糖肽前体蛋白OA-A的活性天然产物为云南臭蛙降血糖肽OA-A1,所述降血糖肽具有下述序列表中的氨基酸序列SEQ ID NO:1:
实施例3云南臭蛙降血糖肽OA-A1的合成与鉴定。
1、云南臭蛙降血糖肽的制备:
根据云南臭蛙降血糖肽OA-A1的氨基酸序列,利用全自动多肽合成仪进行合成,使得其中的2个Cys形成分子内的一对二硫键。通过HPLC反相C18柱层析脱盐、纯化。
2、分子量测定采用快原子轰击质谱法(Fast atom bombardment massspectrometry,FAB-MS),以甘油:间硝基苄醇:二甲亚砜(1:1:1,V:V:V,体积比)为底物,Cs+作为轰击粒子,电流为1μA,发射电压为25Kv。
3、纯化的云南臭蛙降血糖肽OA-A1用高效液相色谱HPLC方法鉴定其纯度,分子量测定采用快原子轰击质谱法,用全自动氨基酸测序仪测定氨基酸序列结构。结果表明所合成云南臭蛙降血糖肽OA-A1具有SEQ ID NO:2所示的氨基酸序列。
4、促胰岛素释放活性检测结果表明:天然纯化和合成的云南臭蛙降血糖肽OA-A1具有相同的生物学功能。
实施例4云南臭蛙降血糖肽OA-A1对小鼠胰岛β细胞增殖和胰岛素分泌的作用。
1)细胞增殖活性检测:利用常规的MTT法进行检测,小鼠胰岛β细胞株(Beta-Tc-6)培养于含10%胎牛血清的培养基中,将1×105cell/ml密度的Bea-Tc-6细胞100μl每孔接种于96孔细胞培养板内,待细胞贴壁后,弃去含血清的培养基,每孔内加入用无胎牛血清培养基溶解的相应浓度的OA-A1样品100μl,空白对照加同体积的培养基。继续培养24小时后,每孔内加入MTT(Promega产品)染液10μl,继续培养4h,可观察到蓝紫色结晶物。吸弃培养液后,每孔加入150μl DMSO(Sigma产品),振摇10min,Tecan公司酶标仪(型号:M200pro)上测定OD570nm,结果见图5A。
2)细胞水平的促胰岛素释放实验:小鼠胰腺β细胞株(Beta-Tc-6)培养于含10%胎牛血清(Biological Industries公司)的DMEM高糖培养基(Biological Industries公司)中,将1×105cell/ml密度的细胞按照100μl每孔接种于96孔细胞培养板(Corning公司产品),37℃,5%CO2恒温培养。待细胞贴壁后,弃去含血清的培养基,每孔内加入用无胎牛血清培养基溶解的相应浓度的多肽样品100μl,空白对照加同体积的无胎牛血清培养基。培养24h后收集培养液,于3000转/min离心30min,收集上清,按照RayBiotech公司胰岛素测定试剂盒方法检测上清液中的胰岛素含量,试剂盒为RayBiotech公司小鼠胰岛素测定试剂盒(货号:ELM-Insulin-1),结果见图5B。
云南臭蛙降血糖肽OA-A1对小鼠胰岛β细胞增殖和胰岛素分泌的作用结果见图5,实验结果表明:云南臭蛙降血糖肽OA-A1在6.25μg/ml-100μg/ml剂量下能显著促进小鼠胰岛β细胞(Beta-Tc-6)的增殖;并在低浓度下(1nM-10nM)可以显著促进Beta-Tc-6细胞胰岛素的释放。
实施例5云南臭蛙降血糖肽OA-A1对糖尿病模型小鼠的作用。
1)昆明小鼠2型糖尿病模型的建立:4周龄的雄性昆明小鼠用高脂饲料连续喂养四周,然后空腹过夜,鼠尾取血,监测血糖(欧姆龙血糖仪及配套试纸),腹腔注链脲佐菌素(STZ,Sigma)65mg/kg连续七天,空腹血糖值大于11.1mmol/L即为造模成功的2型糖尿病小鼠。
2)云南臭蛙降血糖肽OA-A1对2型糖尿病小鼠血糖的影响:2型糖尿病小鼠空腹12小时,实验组皮下注射不同浓度的云南臭蛙降血糖肽OA-A1,阳性对照组皮下注射Exenatide-4(宁波康贝合成,纯度>95%),空白对照皮下注射生理盐水,分别于0h、0.5h、1h、2h、4h、6h监测血糖,并绘制血糖曲线,结果见图6A。
3)云南臭蛙降血糖肽OA-A1对2型糖尿病小鼠葡萄糖耐受能力(OGTT)的影响:2型糖尿病小鼠小鼠空腹12小时,然后实验组皮下注射不同浓度的云南臭蛙降血糖肽OA-A1,阳性对照组注射Exenatide-4,空白对照注射生理盐水,注射完30min后,鼠尾取血测血糖,同时灌胃葡萄糖(湖南科伦制药有限公司)2g/kg,以灌胃葡萄糖起始为0h,随后分别于0.5h、1h、2h、4h测血糖,并绘制血糖变化曲线,结果见图6B。
云南臭蛙降血糖肽OA-A1对糖尿病模型小鼠的作用结果表明:云南臭蛙降血糖肽皮下注射后2-6小时能有效降低未进食糖尿病模型小鼠的血糖(图6A),葡萄糖耐受能力(OGTT)检测结果揭示不同浓度(1nmol/kg-1μmol/kg)云南臭蛙降血糖肽皮下注射均能有效降低进食后糖尿病模型小鼠的血糖,在所有的测试时间点云南臭蛙降血糖肽注射组模型动物的血糖值均低于生理盐水对照组,特别是灌胃葡萄糖后的最初2小时时间段的血糖值(图6B)。
实施例6云南臭蛙降血糖肽OA-A1对糖尿病模型小鼠胰腺的作用。
云南臭蛙降血糖肽OA-A1对小鼠胰腺胰岛细胞的影响:STZ诱导的造模成功2型糖尿病小鼠,随机分组。药物组连续21天皮下注射不同浓度的云南臭蛙降血糖肽OA-A1,对照组连续21天皮下注射生理盐水。第22天动物断颈处死,快速取出胰腺,并用10%甲醛固定,逐级脱水,石蜡包埋切片,常规伊红-苏木精染色,光镜下拍照并染色,结果见图7。
云南臭蛙降血糖肽OA-A1对糖尿病模型小鼠胰腺的作用结果揭示:不同剂量云南臭蛙降血糖肽OA-A1(1nmol/kg-10nmol/kg)能显著促进胰岛细胞的增殖。由于胰岛细胞主要由:1)胰岛β细胞,约占胰岛细胞的60%~80%,可分泌胰岛素,降低血糖;2)胰岛α细胞,约占胰岛细胞的24%~40%,分泌胰高血糖素,胰高血糖素作用同胰岛素相反,可增高血糖;3)胰岛δ细胞,约占胰岛细胞总数的6%~15%,分泌生长抑素以及4)胰岛PP细胞,约占胰岛细胞的1%,分泌胰多肽组成。结合云南臭蛙降血糖肽OA-A1具有显著的促进胰岛β细胞(Beta-Tc-6)增殖的作用(本发明实施例4),提示云南臭蛙降血糖肽OA-A1可通过促进胰岛β细胞的增殖,在整体动物上具有修复受到损伤胰岛细胞的作用,使得因STZ选择性损伤胰腺β-细胞造成2型糖尿病动物模型有显著的胰岛大小恢复正常的趋势(图7,C&D),而2型糖尿病动物模型生理盐水对照胰岛大小(图7,B)与正常小鼠胰岛大小(图7,A)相比则明显萎缩。
<110> 中国科学院昆明动物研究所
<120> 云南臭蛙降血糖肽及制备方法及其应用
<160> 10
<210> 1
<211> 20
<212> PRT
<213> 云南臭蛙(Odorrana andersonii)
<400> 1
Leu Val Gly Lys Leu Leu Lys Gly Ala Val Gly Asp Val Cys
1 5 10
Gly Leu Leu Pro Ile Cys
15 20
<210> 2
<211> 20
<212> DNA
<213> 云南臭蛙(Odorrana andersonii)
<400> 2
atgtttaccc tgaaaaaaag cctgtttctg gtgttttttc tgggc 45
atggtgagcc tgagcctgtg caaacatgaa cgccatgcgg aagaa 90
acccgcgatg atccgaccga agaagaaatt accgcgcgca acgaa 135
gaaaacgtgg aaaaacgcct ggtgggcaaa ctgctgaaag gcgcg 180
gtgggcgatg tgtgcggcct gctgccgatt tgctaa 216
<210> 3
<211> 216
<212> PRT
<213> 云南臭蛙(Odorrana andersonii)
<400> 3
Met Phe Thr Leu Lys Lys Ser Leu Phe Leu Val Phe Phe Leu Gly
-50 -45 -40
Met Val Ser Leu Ser Leu Cys Lys His Glu Arg His Ala Glu Glu
-35 -30 -25
Thr Arg Asp Asp Pro Thr Glu Glu Glu Ile Thr Ala Arg Asn Glu
-20 -15 -10
Glu Asn Val Glu Lys Arg Leu Val Gly Lys Leu Leu Lys Gly Ala
-5 -1 1 5
Val Gly Asp Val Cys Gly Leu Leu Pro Ile Cys
10 15 20
Claims (4)
1.云南臭蛙降血糖肽,其特征在于:所述降血糖肽具有下述序列表中的氨基酸序列SEQID NO:1:
2.权利要求1所述云南臭蛙降血糖肽的制备方法,其特征在于:从云南臭蛙皮肤分泌液中分离得到,纯化的云南臭蛙降血糖肽OA-A1具有SEQ ID NO:1所示的氨基酸序列。
3.权利要求1所述云南臭蛙降血糖肽的制备方法,其特征在于:采用固相化学法合成,合成的云南臭蛙降血糖肽OA-A1具有SEQ ID NO:1所示的氨基酸序列。
4.权利要求1所述云南臭蛙降血糖肽的应用,其特征在于:所述云南臭蛙降血糖肽OA-A1在制备促进胰岛β细胞增殖药物和治疗糖尿病药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611189143.7A CN106749535A (zh) | 2016-12-20 | 2016-12-20 | 云南臭蛙降血糖肽及制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611189143.7A CN106749535A (zh) | 2016-12-20 | 2016-12-20 | 云南臭蛙降血糖肽及制备方法及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106749535A true CN106749535A (zh) | 2017-05-31 |
Family
ID=58896472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611189143.7A Pending CN106749535A (zh) | 2016-12-20 | 2016-12-20 | 云南臭蛙降血糖肽及制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106749535A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101012273A (zh) * | 2007-02-12 | 2007-08-08 | 中国科学院昆明动物研究所 | 无指盘臭蛙分泌肽及其基因和在制药中的应用 |
CN101012274A (zh) * | 2007-02-12 | 2007-08-08 | 中国科学院昆明动物研究所 | 无指盘臭蛙臭蛙肽及其基因和在制药中的应用 |
CN101012275A (zh) * | 2007-02-12 | 2007-08-08 | 中国科学院昆明动物研究所 | 无指盘臭蛙蛙皮肽及其基因和在制药中的应用 |
-
2016
- 2016-12-20 CN CN201611189143.7A patent/CN106749535A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101012273A (zh) * | 2007-02-12 | 2007-08-08 | 中国科学院昆明动物研究所 | 无指盘臭蛙分泌肽及其基因和在制药中的应用 |
CN101012274A (zh) * | 2007-02-12 | 2007-08-08 | 中国科学院昆明动物研究所 | 无指盘臭蛙臭蛙肽及其基因和在制药中的应用 |
CN101012275A (zh) * | 2007-02-12 | 2007-08-08 | 中国科学院昆明动物研究所 | 无指盘臭蛙蛙皮肽及其基因和在制药中的应用 |
Non-Patent Citations (3)
Title |
---|
WEIJIE SHANG等: "Characterization of an insulinotropic peptide from skin secretions of Odorrana andersonii", 《PEPTIDE SCIENCE》 * |
刘炯宇 等: "无指盘臭蛙皮肤抗菌肽的分离纯化与氨基酸序列测定", 《应用于环境生物学报》 * |
李宗杰: "三种蛙皮肤中促胰岛素释放肽的生理活性研究", 《中国优秀硕士学位论文全文数据库(电子期刊)医药卫生科技辑》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Conlon et al. | Antimicrobial peptides from ranid frogs: taxonomic and phylogenetic markers and a potential source of new therapeutic agents | |
Castro et al. | Hylin a1, the first cytolytic peptide isolated from the arboreal South American frog Hypsiboas albopunctatus (“spotted treefrog”) | |
Savelyeva et al. | An overview of Brevinin superfamily: structure, function and clinical perspectives | |
CN101265296B (zh) | 爬行动物cathelicidin抗菌肽及衍生物及其应用 | |
Ueki et al. | Cryptides: functional cryptic peptides hidden in protein structures | |
Conlon et al. | Characterization of antimicrobial peptides from the skin secretions of the Malaysian frogs, Odorrana hosii and Hylarana picturata (Anura: Ranidae) | |
Shang et al. | Molecular cloning of cDNAs encoding antimicrobial peptide precursors from the skin of the Chinese brown frog, Rana chensinensis | |
Scocchi et al. | The salmonid cathelicidins: a gene family with highly varied C-terminal antimicrobial domains | |
Mechkarska et al. | Peptidomic analysis of skin secretions from the bullfrog Lithobates catesbeianus (Ranidae) identifies multiple peptides with potent insulin-releasing activity | |
CN101638432A (zh) | 滇蛙抗氧化肽及其基因和应用 | |
Kawakami et al. | Isolation of biologically active peptides from the venom of Japanese carpenter bee, Xylocopa appendiculata | |
Wang et al. | Molecular cloning and characterization of antimicrobial peptides from skin of the broad-folded frog, Hylarana latouchii | |
CN108676074B (zh) | 一种促肝细胞生长的活性多肽 | |
Mechkarska et al. | Peptidomic analysis of the host-defense peptides in skin secretions of Rana graeca provides insight into phylogenetic relationships among Eurasian Rana species | |
CN106749535A (zh) | 云南臭蛙降血糖肽及制备方法及其应用 | |
CN104356218A (zh) | 少棘蜈蚣镇痛肽前体蛋白Ssm-A及其产物Ssm-A1和Ssm-A2的制备和应用 | |
CN106715459B (zh) | 芋螺毒素多肽κ-CPTx-bt104、其制备方法及应用 | |
CN102516382B (zh) | 一种海南湍蛙抗微生物肽Hainanenin-5及其基因、应用 | |
CN103848914A (zh) | 一种具抗凝活性的菲牛蛭素多肽及其制备方法与用途 | |
Conlon et al. | Peptidomic analysis of skin secretions from Rana heckscheri and Rana okaloosae provides insight into phylogenetic relationships among frogs of the Aquarana species group | |
CN106432483B (zh) | 沼水蛙皮肤丝氨酸蛋白酶抑制肽及其基因和制药应用 | |
Wang et al. | Isolation, characterization and molecular cloning of new antimicrobial peptides belonging to the brevinin-1 and temporin families from the skin of Hylarana latouchii (Anura: Ranidae) | |
CN101845092A (zh) | 家畜驴的一种抗微生物肽Ea-CATH1及其基因和应用 | |
CN107001421B (zh) | 芋螺毒素肽κ-CPTx-btl02、其制备方法及应用 | |
CN102115496A (zh) | 一种抗微生物肽Pc-CATH1及其基因、化学合成方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
AD01 | Patent right deemed abandoned | ||
AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20231013 |